Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17021334 | 0.93 | RPS6KB1 (0.46) | ADORA2BNTRK1AURKARPS6KB1TYK2 | |
| SCHEMBL19010312 | 0.90 | ADORA2B (0.44) | ADORA2BNTRK1TYK2 | |
| SCHEMBL19010298 | 0.89 | NTRK1 (0.48) | ADORA2BNTRK1HPGD | |
| SCHEMBL19010311 | 0.86 | NTRK1 (0.51) | ADORA2BNTRK1TYK2HPGDALDH1A1 | |
| SCHEMBL17021313 | 0.83 | ADORA2B (0.43) | ADORA2BNTRK1AURKARPS6KB1 | |
| SCHEMBL17021327 | 0.81 | NTRK1 (0.48) | ADORA2BNTRK1RPS6KB1HPGD | |
| SCHEMBL19010320 | 0.80 | NTRK1 (0.52) | ADORA2BNTRK1ALDH1A1LMNA | |
| SCHEMBL19010316 | 0.79 | GRM5 (0.48) | ADORA2BNTRK1TYK2HPGDKDM4E | |
| SCHEMBL19010321 | 0.79 | NTRK1 (0.59) | NTRK1TYK2HPGDKDM4EALDH1A1 | |
| SCHEMBL17021403 | 0.78 | NTRK1 (0.49) | ADORA2BNTRK1RPS6KB1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK2, JAK3 | ADORA2B 3086/4885NTRK1 1410/4885AURKA 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.